Literature DB >> 24429228

Xpert MTB/RIF: monitoring response to tuberculosis treatment.

Mark P Nicol1.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24429228     DOI： 10.1016/S2213-2600(13)70133-4

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN： 2213-2600            Impact factor:   30.700


× No keyword cloud information.
  9 in total

1.  Suboptimal specificity of Xpert MTB/RIF among treatment-experienced patients.

Authors:  John Z Metcalfe; Salome Makumbirofa; Beauty Makamure; Reggie Mutetwa; Renée A Peñaloza; Charles Sandy; Wilbert Bara; Stanley Mungofa; Philip C Hopewell; Peter Mason
Journal:  Eur Respir J       Date:  2015-03-18       Impact factor: 16.671

2.  Is Follow-Up Testing with the FilmArray Gastrointestinal Multiplex PCR Panel Necessary?

Authors:  Sholhui Park; Matthew M Hitchcock; Carlos A Gomez; Niaz Banaei
Journal:  J Clin Microbiol       Date:  2017-01-25       Impact factor: 5.948

Review 3.  Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies.

Authors:  Jan Heyckendorf; Sophia B Georghiou; Nicole Frahm; Norbert Heinrich; Irina Kontsevaya; Maja Reimann; David Holtzman; Marjorie Imperial; Daniela M Cirillo; Stephen H Gillespie; Morten Ruhwald
Journal:  Clin Microbiol Rev       Date:  2022-03-21       Impact factor: 50.129

4.  Diagnosis of Concurrent Pulmonary Tuberculosis and Tuberculous Otitis Media Confirmed by Xpert MTB/RIF in the United States.

Authors:  Kathleen M Tompkins; Melissa A Reimers; Becky L White; Michael E Herce
Journal:  Infect Dis Clin Pract (Baltim Md)       Date:  2016-05

Review 5.  Value of Xpert MTB/RIF Using Bronchoalveolar Lavage Fluid for the Diagnosis of Pulmonary Tuberculosis: a Systematic Review and Meta-analysis.

Authors:  Hong-Chao Liu; Yu-Lu Gao; Dan-Feng Li; Xi-Yi Zhao; Yuan-Qing Pan; Chang-Tai Zhu
Journal:  J Clin Microbiol       Date:  2021-03-19       Impact factor: 5.948

6.  The utility of Xpert MTB/RIF performed on bronchial washings obtained in patients with suspected pulmonary tuberculosis in a high prevalence setting.

Authors:  Dewald A Barnard; Elvis M Irusen; Johannes W Bruwer; Danté Plekker; Andrew C Whitelaw; Jacobus D Deetlefs; Coenraad F N Koegelenberg
Journal:  BMC Pulm Med       Date:  2015-09-16       Impact factor: 3.317

7.  Comparison of the Mycobacterium tuberculosis molecular bacterial load assay, microscopy and GeneXpert versus liquid culture for viable bacterial load quantification before and after starting pulmonary tuberculosis treatment.

Authors:  Hoang T Hai; Dao N Vinh; Do D A Thu; Nguyen T Hanh; Nguyen H Phu; Vijay Srinivasan; Guy E Thwaites; Nguyen T T Thuong
Journal:  Tuberculosis (Edinb)       Date:  2019-09-21       Impact factor: 3.131

8.  Mycobactericidal Effects of Different Regimens Measured by Molecular Bacterial Load Assay among People Treated for Multidrug-Resistant Tuberculosis in Tanzania.

Authors:  Peter M Mbelele; Emmanuel A Mpolya; Elingarami Sauli; Bariki Mtafya; Nyanda E Ntinginya; Kennedy K Addo; Katharina Kreppel; Sayoki Mfinanga; Patrick P J Phillips; Stephen H Gillespie; Scott K Heysell; Wilber Sabiiti; Stellah G Mpagama
Journal:  J Clin Microbiol       Date:  2021-03-19       Impact factor: 5.948

9.  Bacterial Loads Measured by the Xpert MTB/RIF Assay as Markers of Culture Conversion and Bacteriological Cure in Pulmonary TB.

Authors:  Shubhada Shenai; Katharina Ronacher; Stefanus Malherbe; Kim Stanley; Magdalena Kriel; Jill Winter; Thomas Peppard; Charles E Barry; Jing Wang; Lori E Dodd; Laura E Via; Clifton E Barry; Gerhard Walzl; David Alland
Journal:  PLoS One       Date:  2016-08-10       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.